Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN versus U GENCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN versus U GENCIN.
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN vs U-GENCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a polypeptide antibiotic that disrupts bacterial cell membrane permeability by interacting with phospholipids. Gramicidin is a polypeptide antibiotic that increases cell membrane permeability by forming ion channels, leading to bacterial cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Instill 2 drops (or appropriate amount) into affected eye(s) every 2-4 hours for 7-10 days. Frequency may be increased to every 1-2 hours in severe infections. Ophthalmic suspension, not for injection.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
None Documented
None Documented
Neomycin: 2-3 hours (normal renal function); polymyxin B: 6-8 hours; gramicidin: ~10 hours (estimated from topical absorption). Prolonged in renal impairment, especially for polymyxin B.
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Renal: ~95% for neomycin (unchanged), minimal for polymyxin B (1-10% unchanged) and gramicidin (<1%). Fecal: 50-60% for polymyxin B (biliary), ~1% for neomycin.
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic